Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease

NEUROBIOLOGY OF DISEASE

卷:48

Article

Quintana, Adrien^1,2  Sgambato-Faure, Veronique¹  Savasta, Marc^1,2,3 

[1] INSERM, U836, Grenoble Inst Neurosci Dynam & Physiopathol Gangl, F-38043 Grenoble, France

[2] Univ Grenoble 1, F-38042 Grenoble, France

[3] CHU Grenoble, F-38043 Grenoble, France

关键词: Parkinson's disease;    Dyskinesia;    6-OHBA lesion;    L-DOPA;    High-frequency stimulation;    Glutamate;    NMDA receptors;    NR2B;    Basal ganglia;   

DOI  :  10.1016/j.nbd.2012.06.009

来源: Elsevier

【 摘 要 】

Dyskinesia is a major side effect of chronic levodopa (L-DOPA) administration, the reference treatment for Parkinson's disease (PD). High-frequency stimulation of the subthalamic nucleus (STN-HFS) alleviates parkinsonian motor symptoms and indirectly improves dyskinesia by decreasing L-DOPA requirement. However, inadequate stimulation can also trigger dyskinetic movements in PD patients and animal models. Here, we investigated the possible association between L-DOPA- and STN-HFS-induced dyskinesia and regulation of the NR2B subunit of NMDA receptors in the rodent model of PD. We subjected 6-OHDA-lesioned rats to HFS for 1 h, at an intensity triggering forelimb dyskinesia. Other 6-OHDA-lesioned rats were treated with chronic high doses of L-DOPA for ten days, to induce abnormal involuntary movements. The 6-OHDA lesion regulated NR2B only in the SNr, where the activation of NR2B was observed (as assessed by phosphorylation of the Tyr(1472) residue). Both STN-HFS and L-DOPA dyskinesiogenic treatments induced NR2B activation in the STN and EP, but only L-DOPA triggered NR2B hyperphosphorylation in the striatum. Finally, the use of CP-101,606 exacerbated L-DOPA-induced motor behavior and associated NR2B hyperphosphorylation in the striatum. STN and EP. Thus. NR2B activation in basal ganglia structures is correlated with dyskinesia. (c) 2012 Elsevier Inc. All rights reserved.

【 授权许可】

Free